News and Updates
CanPath to study the impact and immune response to COVID-19 infection and vaccination
Dec 1, 2021 // Study Updates
The Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study is expanding. The Government of Canada is investing $1.9 million through Canada’s COVID-19 Immunity Task Force (CITF) to fund an extension of CanPath’s existing study over a longer period of time, allowing for an additional collection of blood samples and questionnaire responses from participants. This
Years-early detection of cancer markers possible through research using OHS samples
Nov 26, 2021 // Study Updates
Plasma samples from 330 OHS participants were used to demonstrate that certain markers in the blood could be used to predict cancers up to seven years before a doctor’s diagnosis. Nicholas Cheng, a PhD student in the Awadalla Lab at the Ontario Institute for Cancer Research, presented his research at the October 2021 American Society
Early results from CanPath’s national study confirm antibody levels are stronger after receiving two doses of COVID-19 vaccine
Jun 23, 2021 // Study Updates
Initial preliminary results from the Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study, based on close to 6,000 dried blood spot samples collected between February 8 and May 17, 2021, show a high degree of variability in the level of antibodies produced by a single dose of a COVID-19 vaccine. These findings highlight the importance of
Ontario Health Study begins whole genome sequencing to enrich data holdings
Apr 5, 2021 // Study Updates
The Ontario Health Study is launching an initiative to sequence the whole genomes of more than 40,000 participants from across Ontario. Samples from more than 9,600 Study participants have already been genotyped, using the UKBIObank Affymetrix arrays. Whole genome sequencing, which measures an individual’s entire genome, will provide additional information that will complement the existing
